US8088918B2 - Noncardiotoxic pharmaceutical compounds - Google Patents

Noncardiotoxic pharmaceutical compounds Download PDF

Info

Publication number
US8088918B2
US8088918B2 US11/199,866 US19986605A US8088918B2 US 8088918 B2 US8088918 B2 US 8088918B2 US 19986605 A US19986605 A US 19986605A US 8088918 B2 US8088918 B2 US 8088918B2
Authority
US
United States
Prior art keywords
methyl
phenyl
hydrogen
ester
acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related, expires
Application number
US11/199,866
Other languages
English (en)
Other versions
US20060035863A1 (en
Inventor
Donald L. Barbeau
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
B&G Partners LLC
Original Assignee
Williamsburg Holdings LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Williamsburg Holdings LLC filed Critical Williamsburg Holdings LLC
Priority to US11/199,866 priority Critical patent/US8088918B2/en
Publication of US20060035863A1 publication Critical patent/US20060035863A1/en
Assigned to WILLIAMSBURG HOLDINGS LLC reassignment WILLIAMSBURG HOLDINGS LLC ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: BARBEAU, DONALD L.
Assigned to WILLIAMSBURG HOLDINGS LLC reassignment WILLIAMSBURG HOLDINGS LLC NUNC PRO TUNC ASSIGNMENT (SEE DOCUMENT FOR DETAILS). Assignors: BARBEAU, DONALD L.
Application granted granted Critical
Publication of US8088918B2 publication Critical patent/US8088918B2/en
Assigned to B&G PARTNERS, LLC reassignment B&G PARTNERS, LLC ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: WILLIAMSBURG HOLDINGS, LLC
Expired - Fee Related legal-status Critical Current
Adjusted expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic System
    • C07F9/02—Phosphorus compounds
    • C07F9/06—Phosphorus compounds without P—C bonds
    • C07F9/22—Amides of acids of phosphorus
    • C07F9/24—Esteramides
    • C07F9/2454—Esteramides the amide moiety containing a substituent or a structure which is considered as characteristic
    • C07F9/2458—Esteramides the amide moiety containing a substituent or a structure which is considered as characteristic of aliphatic amines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic System
    • C07F9/02—Phosphorus compounds
    • C07F9/06—Phosphorus compounds without P—C bonds
    • C07F9/22—Amides of acids of phosphorus
    • C07F9/24—Esteramides
    • C07F9/2454—Esteramides the amide moiety containing a substituent or a structure which is considered as characteristic
    • C07F9/2462—Esteramides the amide moiety containing a substituent or a structure which is considered as characteristic of unsaturated acyclic amines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic System
    • C07F9/02—Phosphorus compounds
    • C07F9/06—Phosphorus compounds without P—C bonds
    • C07F9/22—Amides of acids of phosphorus
    • C07F9/24—Esteramides
    • C07F9/2454—Esteramides the amide moiety containing a substituent or a structure which is considered as characteristic
    • C07F9/2466—Esteramides the amide moiety containing a substituent or a structure which is considered as characteristic of cycloaliphatic amines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic System
    • C07F9/02—Phosphorus compounds
    • C07F9/06—Phosphorus compounds without P—C bonds
    • C07F9/22—Amides of acids of phosphorus
    • C07F9/24—Esteramides
    • C07F9/2454—Esteramides the amide moiety containing a substituent or a structure which is considered as characteristic
    • C07F9/247—Esteramides the amide moiety containing a substituent or a structure which is considered as characteristic of aromatic amines (N-C aromatic linkage)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic System
    • C07F9/02—Phosphorus compounds
    • C07F9/06—Phosphorus compounds without P—C bonds
    • C07F9/22—Amides of acids of phosphorus
    • C07F9/24—Esteramides
    • C07F9/2454—Esteramides the amide moiety containing a substituent or a structure which is considered as characteristic
    • C07F9/2475—Esteramides the amide moiety containing a substituent or a structure which is considered as characteristic of aralkylamines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic System
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/553—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having one nitrogen atom as the only ring hetero atom
    • C07F9/5532—Seven-(or more) membered rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic System
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/553—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having one nitrogen atom as the only ring hetero atom
    • C07F9/5532—Seven-(or more) membered rings
    • C07F9/5535—Seven-(or more) membered rings condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic System
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/553—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having one nitrogen atom as the only ring hetero atom
    • C07F9/572—Five-membered rings
    • C07F9/5728—Five-membered rings condensed with carbocyclic rings or carbocyclic ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic System
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/553—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having one nitrogen atom as the only ring hetero atom
    • C07F9/576—Six-membered rings
    • C07F9/58—Pyridine rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic System
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/553—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having one nitrogen atom as the only ring hetero atom
    • C07F9/576—Six-membered rings
    • C07F9/59—Hydrogenated pyridine rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic System
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/645—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having two nitrogen atoms as the only ring hetero atoms
    • C07F9/6503—Five-membered rings
    • C07F9/6506—Five-membered rings having the nitrogen atoms in positions 1 and 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic System
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/645—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having two nitrogen atoms as the only ring hetero atoms
    • C07F9/6509—Six-membered rings
    • C07F9/650952—Six-membered rings having the nitrogen atoms in the positions 1 and 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic System
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6527—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07F9/6533—Six-membered rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic System
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6536—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having nitrogen and sulfur atoms with or without oxygen atoms, as the only ring hetero atoms
    • C07F9/6544—Six-membered rings
    • C07F9/6547—Six-membered rings condensed with carbocyclic rings or carbocyclic ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic System
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/655—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having oxygen atoms, with or without sulfur, selenium, or tellurium atoms, as the only ring hetero atoms
    • C07F9/65515—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having oxygen atoms, with or without sulfur, selenium, or tellurium atoms, as the only ring hetero atoms the oxygen atom being part of a five-membered ring
    • C07F9/65517—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having oxygen atoms, with or without sulfur, selenium, or tellurium atoms, as the only ring hetero atoms the oxygen atom being part of a five-membered ring condensed with carbocyclic rings or carbocyclic ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic System
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/655—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having oxygen atoms, with or without sulfur, selenium, or tellurium atoms, as the only ring hetero atoms
    • C07F9/65525—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having oxygen atoms, with or without sulfur, selenium, or tellurium atoms, as the only ring hetero atoms the oxygen atom being part of a seven-(or more) membered ring
    • C07F9/65527—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having oxygen atoms, with or without sulfur, selenium, or tellurium atoms, as the only ring hetero atoms the oxygen atom being part of a seven-(or more) membered ring condensed with carbocyclic rings or carbocyclic ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic System
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6553—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having sulfur atoms, with or without selenium or tellurium atoms, as the only ring hetero atoms
    • C07F9/655345—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having sulfur atoms, with or without selenium or tellurium atoms, as the only ring hetero atoms the sulfur atom being part of a five-membered ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic System
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
    • C07F9/65583—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system each of the hetero rings containing nitrogen as ring hetero atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic System
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
    • C07F9/65586—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system at least one of the hetero rings does not contain nitrogen as ring hetero atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic System
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Pulmonology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
US11/199,866 2004-08-11 2005-08-09 Noncardiotoxic pharmaceutical compounds Expired - Fee Related US8088918B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US11/199,866 US8088918B2 (en) 2004-08-11 2005-08-09 Noncardiotoxic pharmaceutical compounds

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US60069904P 2004-08-11 2004-08-11
US67354505P 2005-04-21 2005-04-21
US11/199,866 US8088918B2 (en) 2004-08-11 2005-08-09 Noncardiotoxic pharmaceutical compounds

Publications (2)

Publication Number Publication Date
US20060035863A1 US20060035863A1 (en) 2006-02-16
US8088918B2 true US8088918B2 (en) 2012-01-03

Family

ID=35908077

Family Applications (1)

Application Number Title Priority Date Filing Date
US11/199,866 Expired - Fee Related US8088918B2 (en) 2004-08-11 2005-08-09 Noncardiotoxic pharmaceutical compounds

Country Status (10)

Country Link
US (1) US8088918B2 (US08088918-20120103-C00124.png)
EP (1) EP1778252A4 (US08088918-20120103-C00124.png)
JP (1) JP2008509909A (US08088918-20120103-C00124.png)
AU (1) AU2005273961A1 (US08088918-20120103-C00124.png)
CA (1) CA2576530A1 (US08088918-20120103-C00124.png)
IL (1) IL181229A0 (US08088918-20120103-C00124.png)
MX (1) MX2007001713A (US08088918-20120103-C00124.png)
NO (1) NO20071259L (US08088918-20120103-C00124.png)
SG (1) SG169238A1 (US08088918-20120103-C00124.png)
WO (1) WO2006020573A2 (US08088918-20120103-C00124.png)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100105736A1 (en) * 2007-04-12 2010-04-29 Nsab, Filial Af Neurosearch Sweden Ab, Sverige N-oxide and/or di-n-oxide derivatives of dopamine receptor stabilizers/modulators displaying improved cardiovascular side-effects profiles
US9198916B1 (en) * 2014-05-27 2015-12-01 B&G Partners, Llc Compounds and methods for treating tumors
EP2998303A1 (en) 2014-09-17 2016-03-23 B & G Partners, LLC Phenothiazine derivatives and methods for treating tumors

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1881974A4 (en) * 2005-04-21 2011-03-16 Targanta Therapeutics Inc PHOSPHONE FLUOROQUINOLONES, THEIR ANTIBACTERIAL ANALOGUES, AND METHODS FOR PREVENTING AND TREATING BONE AND JOINT INFECTIONS
WO2008050341A2 (en) * 2006-10-25 2008-05-02 Ramot At Tel-Aviv University Ltd Novel psychotropic agents having glutamate nmda activity
US9187439B2 (en) 2011-09-21 2015-11-17 Inception Orion, Inc. Tricyclic compounds useful as neurogenic and neuroprotective agents
CA3037989A1 (en) * 2016-09-29 2018-04-05 Janssen Sciences Ireland Unlimited Company Pyrimidine prodrugs for the treatment of viral infections and further diseases
US11845736B2 (en) 2021-10-01 2023-12-19 Empathbio, Inc. Prodrugs of MDMA, MDA, and derivatives thereof
WO2023129958A2 (en) 2021-12-28 2023-07-06 ATAI Life Sciences AG Nitric oxide releasing prodrugs of mda and mdma

Citations (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2832786A (en) * 1956-02-27 1958-04-29 Wm S Merrell Co Phosphoramides
US2994638A (en) 1958-02-20 1961-08-01 Bayer Ag Agent for combating rodents
US3058879A (en) 1958-10-03 1962-10-16 Bayer Ag Acaricidal and ovicidal agents
US3188309A (en) 1962-03-31 1965-06-08 Asahi Chemical Ind Process for preparing organo-phosphate esters
US4126442A (en) 1978-03-23 1978-11-21 United States Borax & Chemical Corp. O-Phosphoroamidophenylmorpholine compounds and use as herbicides
US4493931A (en) 1981-06-30 1985-01-15 Sanofi Process for the preparation of β-cyclo-substituted ethylamines
US4584132A (en) 1983-08-09 1986-04-22 Hoffmann-La Roche Inc. 1-(N-phosphinylcarbamoyl) β-lactam antibacterial agents
ES2006099A6 (es) * 1988-03-03 1989-04-01 Investchemi S A Procedimiento para la obtencion de hidrocloruro de ciprofloxacina monohidrato.
US5070082A (en) * 1986-10-23 1991-12-03 American Cyanamid Company Solubilized pro-drugs
US5077283A (en) * 1986-10-23 1991-12-31 American Cyanamid Company Solubilized imidazole pro-drugs
US5116827A (en) * 1986-10-23 1992-05-26 American Cyanamid Company Quinolinecarboxylic acid derivatives as solubilized pro-drugs
US5212291A (en) * 1986-10-23 1993-05-18 American Cyanamid Company Anthracycline derivatives as solubilized pro-drugs
US5334741A (en) 1992-07-20 1994-08-02 Research Corporation Technologies, Inc. Phosphorylation with monomeric metaphosphates
US5387748A (en) * 1988-10-24 1995-02-07 Procter & Gamble Pharmaceuticals, Inc. Antimicrobial dithiocarbamoyl quinolones
EP0671389A1 (en) 1994-03-08 1995-09-13 Mitsubishi Chemical Corporation 3-Phenylpyrrolidine derivatives
US5512570A (en) 1994-03-04 1996-04-30 Merck & Co., Inc. Treatment of emesis with morpholine tachykinin receptor antagonists
US5631256A (en) * 1988-10-24 1997-05-20 The Procter & Gamble Company Antimicrobial quinolone thioureas
US5646163A (en) * 1992-10-30 1997-07-08 The Procter & Gamble Company Quinolone 5-(N-heterosubstituted amino) antimicrobials
US5688955A (en) * 1996-03-08 1997-11-18 Adolor Corporation Kappa agonist compounds and pharmaceutical formulations thereof
US5807846A (en) 1996-11-14 1998-09-15 Warner-Lambert Company Phosphonamide ACAT inhibitors
WO1999002531A1 (en) 1997-07-09 1999-01-21 Merck & Co., Inc. Process for synthesizing carbapenem side chain intermediates
US5958905A (en) 1996-03-26 1999-09-28 Texas Biotechnology Corporation Phosphoramidates, phosphinic amides and related compounds and the use thereof to modulate the activity of endothelin
US6521605B1 (en) 1998-07-31 2003-02-18 Eli Lilly And Company Amidophosphate derivatives
US6593374B2 (en) 2000-03-10 2003-07-15 Baylor University Tubulin binding ligands and corresponding prodrug constructs
US6746794B2 (en) * 2001-06-12 2004-06-08 Tech Drive, Inc Thermal runaway inhibitors
US6956054B2 (en) * 1999-02-18 2005-10-18 Baylor University Compositions and methods for use in targeting vascular destruction
US7001926B2 (en) 2000-03-10 2006-02-21 Oxigene, Inc. Tubulin binding agents and corresponding prodrug constructs
WO2006026395A1 (en) 2004-08-26 2006-03-09 Encysive Pharmaceuticals Endothelin a receptor (eta) antagonists in combination with phosphodiesterase 5 inhibitors (pde5) and uses thereof

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ198115A (en) * 1981-08-21 1985-05-31 New Zealand Dev Finance 9-anilinoacridines;pharmaceutical compositions
US4824850A (en) * 1982-05-18 1989-04-25 University Of Florida Brain-specific drug delivery
EP0338372A3 (en) * 1988-04-22 1991-10-09 American Cyanamid Company Solubilized pro-drugs
RU1786037C (ru) * 1991-05-05 1993-01-07 Институт биоорганической химии и нефтехимии АН УССР N-Замещенные фосфамиды, обладающие ювенильно-гормональной активностью
JPH07300455A (ja) * 1994-03-08 1995-11-14 Mitsubishi Chem Corp ３−フェニルピロリジン誘導体
US6214812B1 (en) * 1998-04-02 2001-04-10 Mbc Research, Inc. Bisphosphonate conjugates and methods of making and using the same
JP2000080094A (ja) * 1998-07-02 2000-03-21 Sankyo Co Ltd ５員ヘテロアリ―ル化合物
AU777725B2 (en) * 1999-09-17 2004-10-28 Baylor University Indole-containing and combretastatin-related anti-mitotic and anti-tubulin polymerization agents
JP2004523480A (ja) * 2000-08-22 2004-08-05 ニュー リバー ファーマシューティカルズ， インコーポレイテッド 活性作用物質送達系ならびに活性作用物質の保護および投与方法
WO2004064728A2 (en) * 2003-01-16 2004-08-05 Paratek Pharmaceuticals, Inc. Use of specific tetracycline compounds in therapy

Patent Citations (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2832786A (en) * 1956-02-27 1958-04-29 Wm S Merrell Co Phosphoramides
US2994638A (en) 1958-02-20 1961-08-01 Bayer Ag Agent for combating rodents
US3058879A (en) 1958-10-03 1962-10-16 Bayer Ag Acaricidal and ovicidal agents
US3188309A (en) 1962-03-31 1965-06-08 Asahi Chemical Ind Process for preparing organo-phosphate esters
US4126442A (en) 1978-03-23 1978-11-21 United States Borax & Chemical Corp. O-Phosphoroamidophenylmorpholine compounds and use as herbicides
US4493931A (en) 1981-06-30 1985-01-15 Sanofi Process for the preparation of β-cyclo-substituted ethylamines
US4584132A (en) 1983-08-09 1986-04-22 Hoffmann-La Roche Inc. 1-(N-phosphinylcarbamoyl) β-lactam antibacterial agents
US5070082A (en) * 1986-10-23 1991-12-03 American Cyanamid Company Solubilized pro-drugs
US5077283A (en) * 1986-10-23 1991-12-31 American Cyanamid Company Solubilized imidazole pro-drugs
US5116827A (en) * 1986-10-23 1992-05-26 American Cyanamid Company Quinolinecarboxylic acid derivatives as solubilized pro-drugs
US5212291A (en) * 1986-10-23 1993-05-18 American Cyanamid Company Anthracycline derivatives as solubilized pro-drugs
ES2006099A6 (es) * 1988-03-03 1989-04-01 Investchemi S A Procedimiento para la obtencion de hidrocloruro de ciprofloxacina monohidrato.
US5387748A (en) * 1988-10-24 1995-02-07 Procter & Gamble Pharmaceuticals, Inc. Antimicrobial dithiocarbamoyl quinolones
US5631256A (en) * 1988-10-24 1997-05-20 The Procter & Gamble Company Antimicrobial quinolone thioureas
US5672600A (en) * 1988-10-24 1997-09-30 The Procter & Gamble Company Antimicrobial dithiocarbamoyl quinolones
US5334741A (en) 1992-07-20 1994-08-02 Research Corporation Technologies, Inc. Phosphorylation with monomeric metaphosphates
US5646163A (en) * 1992-10-30 1997-07-08 The Procter & Gamble Company Quinolone 5-(N-heterosubstituted amino) antimicrobials
US5691336A (en) 1994-03-04 1997-11-25 Merck & Co., Inc. Morpholine compounds are prodrugs useful as tachykinin receptor antagonists
US5512570A (en) 1994-03-04 1996-04-30 Merck & Co., Inc. Treatment of emesis with morpholine tachykinin receptor antagonists
EP0671389A1 (en) 1994-03-08 1995-09-13 Mitsubishi Chemical Corporation 3-Phenylpyrrolidine derivatives
US5688955A (en) * 1996-03-08 1997-11-18 Adolor Corporation Kappa agonist compounds and pharmaceutical formulations thereof
US5958905A (en) 1996-03-26 1999-09-28 Texas Biotechnology Corporation Phosphoramidates, phosphinic amides and related compounds and the use thereof to modulate the activity of endothelin
US5807846A (en) 1996-11-14 1998-09-15 Warner-Lambert Company Phosphonamide ACAT inhibitors
WO1999002531A1 (en) 1997-07-09 1999-01-21 Merck & Co., Inc. Process for synthesizing carbapenem side chain intermediates
US6521605B1 (en) 1998-07-31 2003-02-18 Eli Lilly And Company Amidophosphate derivatives
US6956054B2 (en) * 1999-02-18 2005-10-18 Baylor University Compositions and methods for use in targeting vascular destruction
US6593374B2 (en) 2000-03-10 2003-07-15 Baylor University Tubulin binding ligands and corresponding prodrug constructs
US7001926B2 (en) 2000-03-10 2006-02-21 Oxigene, Inc. Tubulin binding agents and corresponding prodrug constructs
US6746794B2 (en) * 2001-06-12 2004-06-08 Tech Drive, Inc Thermal runaway inhibitors
WO2006026395A1 (en) 2004-08-26 2006-03-09 Encysive Pharmaceuticals Endothelin a receptor (eta) antagonists in combination with phosphodiesterase 5 inhibitors (pde5) and uses thereof

Non-Patent Citations (60)

* Cited by examiner, † Cited by third party
Title
Basarab et al. Bioorganic & Medicinal Chemistry (2002), 10(12),4143-4154. *
Caplus English Abstract, DN 113:40732, L. Molina et al., ES 2006099, 1989.
Caplus English Abstract, DN 134:28996, T. Gajda et al., See RN #118132-91-5, 2000.
Caplus English Abstract, DN 56:45951, M.G. Campen et al., See RN #95159-07-2, 1961.
Caplus English Abstract, DN 99:207981, J. Kaszubska et al., See RN #87834-89-7, 1983.
Cates et al. Journal of Pharmaceutical sciences, 1966, 55(12), 1400-1405. *
Chemical Abstract, CAS registry No. 1892-18-8.
Chemical Abstract, CAS registry No. 22700-45-4.
Chemical Abstract, CAS registry No. 22767-82-4.
Chemical Abstract, CAS registry No. 22846-97-5.
Chemical Abstract, CAS registry No. 25627-01-4.
Chemical Abstract, CAS registry No. 26245-77-2.
Chemical Abstract, CAS registry No. 3848-51-9.
Chemical Abstract, CAS registry No. 4972-36-5.
Chemical Abstract, CAS registry No. 51287-66-2.
Chemical Abstract, CAS registry No. 52670-78-7.
Chemical Abstract, CAS registry No. 5786-71-0.
Chemical Abstract, CAS registry No. 6345-18-2.
Chemical Abstract, CAS registry No. 90008-29-0.
Dasu Ramaswami & Ernst R. Kirch, Anticonvulsant and Growth Inhibitory Effects of Some Organophosphorus Compounds, Journal of the American Pharmaceutical Association, vol. XLII, No. 8, Aug. 1953, pp. 495-497.
F.D. Tattersall, et al., The Novel NK1 Receptor Antagonist MK-0869 (L-754,030) and its Water Soluble Phosphoryl Prodrug, L-758,298, Inhibit Acute and Delayed Cisplatin-Induced Emesis in Ferrets, Neuropharmacology, vol. 39, 2000, pp. 652-663.
G. Halliwell et al., A Comparison of Imipramine, Chlorpromazine and Related Drugs in Various Tests Involving Autonomic Functions and Antagonism of Reserpine, 23 Brit. J. Pharmacol. 330, 330 (1964).
G.S. Basarab et al., "Design of Inhibitors of Scytalone Dehydratase: Probing Interactions with an Asparagine Carboxamide," Bioorganic & Medicinal Chemistry 10 (2002), 4143-54.
Gajda et al. Polish Journal of Chemistry (2000), 74(10), 1385-1387. *
Gazaliev et al. Khimiya Prirodnykh Soedinenii (1989), (4), 584-5. *
Goument et al. STN Accession No. 1994:244208, Document No. 120:244208, Abstract of Bulletin de la Societe Chimique de France (1993), 130(4),450-8. *
H. J. Lee, W. S. Fillers, & M.R. Iyengar, Phosphocreatine, an Intracellular High-Energy Compound, Is Found in the Extracellular Fluid of the Seminal Vesicles in Mice and Rats, Proc. Natl. Acad. Sci., vol. 85, Oct. 1988, pp. 7265-7269.
Hemenway et al Journal of organic chemistry (1999) 64(17), 6312-6318. *
Hugo Garrido-Hernandez, Kyung D. Moon, Robert L. Geahlen, & Richard F. Borch, Design and Synthesis of Phosphotyrosine Peptidomimetic Prodrugs, Journal of Medicinal Chemistry, 2006, vol. 49, No. 11, pp. 3368-3376.
Jeffrey J. Hale, et al., Phosphorylated Morpholine Acetal Human Neurokinin-1 Receptor Antagonists as Water-Soluble Prodrugs, Journal of Medicinal Chemistry, 2000, vol. 43, No. 6, pp. 1234-1241.
John Hinton, Psychotropic Drugs, 44 Postgrad. Med. J. 286, 292 (1968).
Julian R.A. Wooltorton & Alistair Mathie, Block of Potassium Currents in Rat Isolated Sympathetic Neurones by Tricyclic Antidepressants and Structurally Related Compounds, 110 Br. J. Pharmacol. 1126 (1993).
K.C. Murdock, et al., N-Phosphoryl Derivatives of Bisantrene. Antitumor Prodrugs with Enhanced Solubility and Reduced Potential for Toxicity, Journal of Medicinal Chemistry, 1993, vol. 36, No. 15, pp. 2098-2101.
Kaszubska et al. Journal of Environmental Science and Health, Part B: Pesticides, Food Contaminants, and Agricultural Wastes (1983), B18(4-5), 515-27. *
Keiko Kitagishi & Keitaro Hiromi, Binding Between Thermolysin and its Specific Inhibitor, N-Phosphoryl-L-Leucyl-L-Tryptophan (PLT), J. Biochem., vol. 99, No. 1., 1986, pp. 191-197.
L. A. Cates, W. H. Lawrence, & R. J. McClain, Phosphorus-Nitrogen Compounds VI: Some Phenethylamine Derivatives, Journal of Pharmaceutical Sciences, vol. 55, No. 12, Dec. 1966, pp. 1400-1405.
L.A. Cates, R.L. Gallio, & M.B. Cramer, Phosphorus-Nitrogen Compounds XV: N-1-Adamantylphosphoramidic Dichloride and Dimethyl and Diphenyl N-1-Adamantylphosphoramidate, Journal of Pharmaceutical Sciences, vol. 62, No. 10, Oct. 1973, pp. 1719-1720.
Lindley A. Cates & Noel M. Ferguson, Phosphorus-Nitrogen Compounds IV. Some 2-Aminopyridine Derivatives, Journal of Pharmaceutical Sciences, vol. 54, No. 3, Mar. 1965, pp. 465-466.
Lindley A. Cates & Noel M. Ferguson, Phosporus-Nitrogen Compounds V. Some Guanidine and 2-Aminopyrimidine Derivatives, Journal of Pharmaceutical Sciences, vol. 55, No. 9, Sep. 1966, pp. 966-969.
Lindley A. Cates & Ven-Shun Li, Phosphorus-Nitrogen Compounds XXIII: Oncolytic Phosphorylated Imines, Journal of Pharmaceutical Sciences, vol. 71, No. 3, Mar. 1982, pp. 308-311.
Lindley A. Cates, Phosphorus-Nitrogen Compounds. 12. Phosphamidase Studies. 2. N-Alkylphosphoramidic Acids, Journal of Medicinal Chemistry, 1971, vol. 14, No. 7, pp. 647-649.
Lindley A. Cates, Phosphorus-Nitrogen Compounds. IX. Hydroxylamine Derivatives, Journal of Medicinal Chemistry, vol. 11, No. 2, 1968, pp. 382-383.
Lindley A. Cates, Phosphorus-Nitrogen Compounds. XI. Phosphamidase Studies. I. Unsubstituted Amides, Journal of Medicinal Chemistry, vol. 13, No. 2, 1970, p. 301-302.
Lindley A. Cates, Ven-Shun Li, & Sharathchandra S. Hegde, Phosphorus-Nitrogen Compounds. 31. N-Phosphinylamino-1,2,5,6-tetrahydropyridines: Analgesic Activity and Effect on Blood Glucose, Pharmaceutical Research, vol. 6, No. 8, 1989, pp. 737-739.
M.P. Gamble et al., "A Novel Phosphinamide Catalyst for the Assymetric Reduction of Ketones by Borane," J. Org. Chem. 1998, 63, pp. 6068-6071.
M.S. Hemenway et al., "Syntheses of New Phosphorus-Containing Azabicycloalkanes and Their Microbial Hydroxylation Using Beauveria bassiana," J. Org. Chem. 1999 64, 6312-6318.
M.T. Garcia-Lopez, R. Gonzalez Muniz, R. Herranz, H. Bravo, J.R. Naranjo, & J. Del Rio, Synthesis and Analgesic Properties of N-Phosphorylated Derivatives of Phe-Ala and Phe-Gly, Int. J. Peptide Protein Res. vol. 26, 1985, pp. 174-178.
McCarty et al. Journal of Organic Chemistry (1961), 26, 4084. *
Nguyen-Hai Nam, et al., Water Soluble Prodrugs of the Antitumor Agent 3-[(3-Amino-4-methoxy) phenyl]-2-(3,4,5,-trimethoxyphenypcyclopent-2-ene-1-one, Bioorganic & Medicinal Chemistry, vol. 11, 2003, pp. 1021-1029.
PubChem, Compound Identification No. 2272818.
PubChem, Compound Identification No. 2302418.
PubChem, Compound Identification No. 2305281.
PubChem, Compound Identification No. 263590.
PubChem, Compound Identification No. 267208.
PubChem, Compound Identification No. 605821.
Q. Xiao et al., "Facile Synthesis of 3B-Cholesterol H-Phosphonates," Chemistry Letters vol. 32 No. 6 (2003), pp. 522-523.
Sakhibullina et al. US Zhurnal Obshchei Khimii (1991), 61(11), 2419-20. *
Su-Er W. Huskey, et al., Substance P Receptor Antagonist I: Conversion of Phosphoramidate Prodrug After I.V. Administration to Rats and Dogs, Drug Metabolism and Disposition, vol. 27, No. 11, 1999, pp. 1367-1373.
Victor D. Warner, Dale B. Mirth, & Adrienne S. Dey, Synthesis of Diethyl N-Dodecylphosphoramidate Analogs as Potential Inhibitors of Dental Plaque, Journal of Medicinal Chemistry, vol. 16, No. 10, 1973, pp. 1185-1186.
Y.W. Wu et al., "Sythesis, In Vitro Anticancer Evaluation, and Interference with Cell Cyle Progression . . . ," Nucl., Nucleos. & Nucl. Acid., 23, 2004, 1797-1811.

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100105736A1 (en) * 2007-04-12 2010-04-29 Nsab, Filial Af Neurosearch Sweden Ab, Sverige N-oxide and/or di-n-oxide derivatives of dopamine receptor stabilizers/modulators displaying improved cardiovascular side-effects profiles
US9198916B1 (en) * 2014-05-27 2015-12-01 B&G Partners, Llc Compounds and methods for treating tumors
EP2998303A1 (en) 2014-09-17 2016-03-23 B & G Partners, LLC Phenothiazine derivatives and methods for treating tumors

Also Published As

Publication number Publication date
MX2007001713A (es) 2007-07-13
SG169238A1 (en) 2011-03-30
AU2005273961A1 (en) 2006-02-23
CA2576530A1 (en) 2006-02-23
IL181229A0 (en) 2007-07-04
EP1778252A4 (en) 2010-01-27
NO20071259L (no) 2007-03-09
JP2008509909A (ja) 2008-04-03
US20060035863A1 (en) 2006-02-16
EP1778252A2 (en) 2007-05-02
WO2006020573A3 (en) 2009-04-16
WO2006020573A2 (en) 2006-02-23

Similar Documents

Publication Publication Date Title
US8088918B2 (en) Noncardiotoxic pharmaceutical compounds
USRE39558E1 (en) 5-Substituted-6-cyclic-5,6,7,8-tetrahydronaphthalen 2-ol compounds which are useful for treating osteoporosis
US7101887B2 (en) 1-phenyl-4-benzylpiperazines dopamine receptor subtype specific ligands
US20060172992A1 (en) Therapeutic agent for overactive bladder resulting from cerebral infarction
EP0563345B1 (en) Novel 4-arylpiperazines and 4-arylpiperidines
US20090137629A1 (en) Sigma receptor binding agent containing indanone derivative
US6569849B1 (en) N-Substituted azaheterocyclic compounds
JP2004511544A (ja) 化合物
WO1997009046A1 (en) Compounds and methods
CN103420942A (zh) 对乙、丁酰胆碱酯酶具有双重抑制活性化合物
IE910020A1 (en) Piperidine and pyrrolidine derivatives
US5019574A (en) 3,4-diaminoquinoline and 3,4-diamino-5,6,7,8-tetrahydroquinoline compounds useful for improving psychoneural function
US20060135507A1 (en) Therapeutic agent for overactive bladder involved in aging
EP1123702A1 (en) Analgesics
US20120142735A1 (en) Disubstituted [4-(5-aminomethyl-phenyl)-piperidin-1-yl]- 1h-indol-3-yl]-methanones
AP424A (en) Piperidine derivatives, their preparation and their application in therapy.
JPH0657693B2 (ja) ムスカリン様レセプター拮抗薬
US20130005709A1 (en) Sulfone compounds as 5-ht6 receptor ligands
US20100317666A1 (en) Composition Comprising An NK-1 Receptor Antagonist And An SSRI For The Treatment Of Tinnitus And Hearing Loss
US20050256308A1 (en) Spiro compounds, medicinal compositions containing the same and intermediates of the compounds
US20070135445A1 (en) Bicyclic Indolyl Derivatives and Methods for Their Use as Serotonergic Agents
CN101432003A (zh) 非心脏毒性药物化合物
CA2128699A1 (en) Use of 3-arylindole and 3-arylindazole derivatives for the treatment of psychoses
JPH09509143A (ja) 置換アミノアルキルアミノピリジン
WO1995011239A1 (fr) Nouveau derive de phenoxyalkylpiperazine

Legal Events

Date Code Title Description
AS Assignment

Owner name: WILLIAMSBURG HOLDINGS LLC, ILLINOIS

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:BARBEAU, DONALD L.;REEL/FRAME:019188/0307

Effective date: 20070320

AS Assignment

Owner name: WILLIAMSBURG HOLDINGS LLC, ILLINOIS

Free format text: NUNC PRO TUNC ASSIGNMENT;ASSIGNOR:BARBEAU, DONALD L.;REEL/FRAME:019279/0427

Effective date: 20070510

AS Assignment

Owner name: B&G PARTNERS, LLC, ILLINOIS

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:WILLIAMSBURG HOLDINGS, LLC;REEL/FRAME:028350/0534

Effective date: 20120529

REMI Maintenance fee reminder mailed
LAPS Lapse for failure to pay maintenance fees
STCH Information on status: patent discontinuation

Free format text: PATENT EXPIRED DUE TO NONPAYMENT OF MAINTENANCE FEES UNDER 37 CFR 1.362

FP Lapsed due to failure to pay maintenance fee

Effective date: 20160103